Current:Home > ScamsFDA approves Zepbound, a new obesity drug that will take on Wegovy -Momentum Wealth Path
FDA approves Zepbound, a new obesity drug that will take on Wegovy
View
Date:2025-04-14 12:16:29
An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy.
Eli Lilly & Co., maker of Zepbound, says it shows greater weight loss at a lower list price than Wegovy. The Lilly drug will be available in the U.S. by the end of the year. A version of the shot, known generically as tirezepatide, is already sold as Mounjaro to treat Type 2 diabetes.
The Lilly drug works by acting on two hormone receptors in the brain, including one called GLP-1, short for glucagon-like peptide-1 – that regulate appetite and metabolism.
The new class of medicines for managing obesity that includes Zepbound and Wegovy has given people with obesity and overweight a potent option for treatment. But the drugs are expensive, and many people who lose weight regain it after stopping the medicines.
Dramatic loss in weight
In clinical trials, the average weight loss for people taking Zepbound was about 20%. One in three users of the medication at its highest dose, saw weight loss of about a quarter of their body weight. The results are roughly equivalent to those of bariatric surgery.
Common side effects from the drug include nausea, diarrhea, constipation and vomiting. The drug also caused thyroid tumors in rats, though the FDA said it's not known if Zepbound causes the same kind of tumors in humans.
In announcing the approval, the FDA cited the growing public health concern over excess weight. "In light of increasing rates of both obesity and overweight in the United States, today's approval addresses an unmet medical need," said Dr. John Sharretts, director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDA's Center for Drug Evaluation and Research. About 70% of adult Americans have obesity or overweight, the FDA noted.
"New treatment options bring hope to the many people with obesity who struggle with this disease," said Joe Nadglowski, president and CEO of the Obesity Action Coalition, in a statement released by Lilly. He noted numerous life-threatening diseases — from heart attacks and strokes to diabetes — that are linked to obesity.
Cost and insurance coverage
New medications to treat obesity and related conditions have become wildly popular, but are expensive, especially when paid for out of pocket.
Zepbound will carry a list price of $1,060, which would make it about 20% less than the list price for Wegovy, Lilly said.
The actual amount patients would pay would depend on their insurance coverage and potential discounts. Insurance coverage for Wegovy, for example, varies widely by provider.
Lilly said people with commercial health insurance that covers Zepbound "may be eligible to pay as low as $25" for one-month or three-month prescriptions.
Lilly will offer a discount card to help defray the expense for people who have commercial health insurance that doesn't include coverage for the drug. The cost could be reduced to $550 for a one-month prescription of Zepbound, or about half the list price, Lilly said.
Medicare doesn't pay for weight-loss drugs. However, Congress is considering measures that would expand insurance access to cover treatments for obesity, including some of the new medications, for Medicare enrollees.
"Far too many hurdles continue to prevent people living with obesity from accessing obesity treatments that could lead to significant weight loss," said Mike Mason, executive vice president and president of Lilly's Diabetes and Obesity division in a statement, calling for the government and insurance industry to cover Zepbound.
veryGood! (38)
Related
- Former Danish minister for Greenland discusses Trump's push to acquire island
- A group of Japanese citizens launches a lawsuit against the police to stop alleged ‘racial profiling’
- A group of Japanese citizens launches a lawsuit against the police to stop alleged ‘racial profiling’
- Tom Selleck reveals lasting 'Friends' memory in tribute to 'most talented' Matthew Perry
- Why we love Bear Pond Books, a ski town bookstore with a French bulldog 'Staff Pup'
- The head of a Saudi royal commission has been arrested on corruption charges
- Ashley Park Shares Health Update After Hospitalization for Septic Shock
- Country music star Chris Young cleared of all charges after arrest in Nashville bar
- McConnell absent from Senate on Thursday as he recovers from fall in Capitol
- Transitional housing complex opens in Atlanta, cities fight rise in homelessness
Ranking
- Selena Gomez's "Weird Uncles" Steve Martin and Martin Short React to Her Engagement
- International Holocaust Remembrance Day marks 79th anniversary of Auschwitz liberation
- USA Hockey will mandate neck laceration protection for players under 18 effective Aug. 1
- 49ers vs. Lions highlights: How San Francisco advanced to Super Bowl 58 vs. Chiefs
- Small twin
- Finland’s presidential election runoff to feature former prime minister and ex-top diplomat
- Toyota chief apologizes for cheating on testing at group company _ again
- Americans don't sleep enough. The long-term effects are dire, especially for Black people
Recommendation
Sam Taylor
A group of Japanese citizens launches a lawsuit against the police to stop alleged ‘racial profiling’
Report: California officers shot in ambush were not verbally warned that suspect had gun, was on PCP
Charles Osgood: Baltimore boy
Rylee Arnold Shares a Long
Chiefs' path back to Super Bowl stage looked much different than past runs
Demand for minerals sparks fear of mining abuses on Indigenous peoples' lands
'Vanderpump Rules,' 'Scandoval' and a fight that never ends